Safety and Tolerability of PCK3145, a Synthetic Peptide Derived from Prostate Secretory Protein 94 (PSP94) in Metastatic Hormone-Refractory Prostate Cancer
- 1 September 2005
- journal article
- research article
- Published by Elsevier BV in Clinical Prostate Cancer
- Vol. 4 (2), 91-99
- https://doi.org/10.3816/cgc.2005.n.016
Abstract
No abstract availableKeywords
This publication has 23 references indexed in Scilit:
- Cancer Statistics, 2005CA: A Cancer Journal for Clinicians, 2005
- Docetaxel plus Prednisone or Mitoxantrone plus Prednisone for Advanced Prostate CancerThe New England Journal of Medicine, 2004
- Current strategies in the management of hormone refractory prostate cancerCancer Treatment Reviews, 2003
- A Randomized, Placebo-Controlled Trial of Zoledronic Acid in Patients With Hormone-Refractory Metastatic Prostate CarcinomaJNCI Journal of the National Cancer Institute, 2002
- State-of-the-Art Treatment of Metastatic Hormone-Refractory Prostate CancerThe Oncologist, 2002
- Prognostic significance of ?-microseminoprotein mRNA expression in prostate cancerThe Prostate, 1999
- Long-Term (15 Years) Results After Radical Prostatectomy For Clinically Localized (Stage T2c Or Lower) Prostate CancerJournal of Urology, 1994
- Patterns of care and rtog studies in prostate cancer: Long-term survival, hazard rate observations, and possibilities of cureInternational Journal of Radiation Oncology*Biology*Physics, 1994
- Effect of prostatic inhibin peptide (PIP) on prostate cancer cell growth in vitro and in vivoThe Prostate, 1993
- Beta‐microseminoprotein immunoreactivity as a new prognostic indicator of prostatic carcinomaThe Prostate, 1993